SEC Form 10-K filed by Cullinan Therapeutics Inc.
$CGEM
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/11/2025 | $22.00 | Buy | Stifel |
| 10/24/2024 | $30.00 | Buy | UBS |
| 5/1/2024 | $40.00 | Buy | Stifel |
| 4/15/2024 | Outperform | William Blair | |
| 2/15/2024 | $30.00 | Outperform | Wedbush |
| 6/15/2023 | Outperform | TD Cowen | |
| 11/21/2022 | $20.00 | Buy | BTIG Research |
Stifel resumed coverage of Cullinan Therapeutics with a rating of Buy and set a new price target of $22.00
UBS initiated coverage of Cullinan Therapeutics with a rating of Buy and set a new price target of $30.00
Stifel initiated coverage of Cullinan Management with a rating of Buy and set a new price target of $40.00